Michael Trembley, Ph.D.
Scientist II
Michael Trembley is a scientist II at the Precision Cardiology Laboratory (PCL) of the Ó³»´«Ã½ and Bayer, where his research is focused on discovering and validating novel therapeutic targets for heart disease. His work leverages advanced screening platforms and engineered human stem cell models to drive innovations in heart failure treatment.
Before joining PCL, Trembley served as an instructor and research fellow at Boston Children's Hospital and Harvard Medical School. There, he led a multidisciplinary team of biologists, bioengineers, and clinicians in the NIH Tissue Chips Consortium, where they developed cell-based platforms to model cardiomyopathies. His research employed genetic engineering and 3D tissue models to investigate the molecular mechanisms of conduction defects in pediatric patients with inherited arrhythmias.
Trembley holds a Ph.D. in pharmacology from the University of Rochester. During his doctoral training at the Aab Cardiovascular Institute, he utilized rodent models of heart failure to explore the signaling pathways activated by pressure overload in the heart.
October 2024
